Bristol-Myers Squibb Company (BMY)

NYSE: BMY · Real-Time Price · USD
46.86
-1.66 (-3.42%)
At close: Jul 11, 2025, 4:00 PM
46.90
+0.04 (0.09%)
After-hours: Jul 11, 2025, 7:59 PM EDT
-3.42%
Market Cap 95.36B
Revenue (ttm) 47.64B
Net Income (ttm) 5.42B
Shares Out 2.04B
EPS (ttm) 2.67
PE Ratio 17.55
Forward PE 7.52
Dividend $2.48 (5.29%)
Ex-Dividend Date Jul 3, 2025
Volume 13,716,440
Open 47.75
Previous Close 48.52
Day's Range 46.72 - 47.80
52-Week Range 39.93 - 63.33
Beta 0.37
Analysts Hold
Price Target 58.00 (+23.77%)
Earnings Date Jul 31, 2025

About BMY

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for oncology, hematology, immunology, cardiovascular, neuroscience, and other areas. The company’s products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation and for the treatment of DVT/PE; Opdivo for various anti-cancer indications; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthrit... [Read more]

Sector Healthcare
Founded 1887
Employees 34,100
Stock Exchange NYSE
Ticker Symbol BMY
Full Company Profile

Financial Performance

Financial Statements

Analyst Summary

According to 16 analysts, the average rating for BMY stock is "Hold." The 12-month stock price target is $58.0, which is an increase of 23.77% from the latest price.

Price Target
$58.0
(23.77% upside)
Analyst Consensus: Hold
Stock Forecasts

News

Dogs Of The S&P 500: 14 Ideal 'Safer' July Dividend Buys

High-yield S&P 500 stocks can be risky, but 14 "safer" S&P 500 dividend dogs have strong free cash flow to support payouts and are attractive buys. Analyst forecasts suggest top ten S&P 500 dividend d...

Other symbols: AESAMCRARECAGCPBCVXD
1 day ago - Seeking Alpha

Dividend Harvesting Portfolio Week 227: $22,700 Allocated, $2,385.24 In Projected Dividends

The Dividend Harvesting Portfolio hit new all-time highs in value, profitability, and forward income, with a 29.58% return on invested capital. Consistent weekly investing, diversification, and a focu...

Other symbols: BPENBMOSLGTFC
2 days ago - Seeking Alpha

Bristol Myers Squibb: Hidden Facts Blur The Strength Of The Company

Bristol Myers Squibb is undervalued despite the looming patent cliff, as its robust pipeline and strong cash flow position it for future growth. The impact of Eliquis' patent expiry is overstated, sin...

3 days ago - Seeking Alpha

June Readers Tagged 13 Ideal Dividend Dogs From 16 "Safer" Out Of 38 ReFa/Ro

My contrarian yield-based strategy spotlights high-yield 'ReFa/Ro Dogs' with analyst forecasts suggesting 19-33% net gains by June 2026. All top ten ReFa/Ro Dogs offer annual dividends from $1,000 inv...

Other symbols: ABRAGNCCAGCPBDOWDXECC
4 days ago - Seeking Alpha

Healthy Returns: Medicaid cuts in Trump's megabill may affect some drugmakers more than others

Trump's "big beautiful" bill will also affect the pharmaceutical industry, while AI startups have pulled in the majority of digital health funding this year.

Other symbols: GILDJNJNVOPFEVRTX
4 days ago - CNBC

2 Wonderful Dividends At Bargain Basement Prices

Uncertainty creates value opportunities. In this article, I highlight two value stocks trading far below their historical valuations. Both offer dividend yields that are well above historical average ...

Other symbols: REXR
5 days ago - Seeking Alpha

Bristol-Myers Squibb: Strong Launch Portfolio Amid Market Reset

Initiate Bristol-Myers Squibb (BMY) with Buy and $57 PT, driven by high-momentum launches, robust pipeline, and underappreciated growth portfolio outperformance. BMY's $13bn+ annual FCF, strong balanc...

11 days ago - Seeking Alpha

Bristol-Myers Squibb: You Might Wish You Bought More Now (Upgrade)

Bristol-Myers Squibb faces structural headwinds from legacy product losses, but its strong free cash flow and undervalued stock price provide downside protection. The recent $11B partnership with BioN...

13 days ago - Seeking Alpha

U.S. Food and Drug Administration Approves Streamlined Patient Monitoring Requirements and Removal of REMS Programs within Bristol Myers Squibb's Cell Therapy Labels

PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #Abecma--U.S. FDA Approves Streamlined Patient Monitoring Requirements and Removal of REMS Programs within Bristol Myers Squibb's Cell Therapy Labels.

16 days ago - Business Wire

New vaccine panel meeting underway

CNBC's Angelica Peebles joins 'Squawk on the Street' to discuss the latest news on vaccines.

Other symbols: BDXMRKUNHZBH
16 days ago - CNBC Television

Cigna sues Bristol Myers over alleged monopoly for multiple myeloma drug Pomalyst

Cigna sued Bristol Myers on Tuesday, accusing the drugmaker of violating federal antitrust law by maintaining a monopoly over a blockbuster multiple myeloma drug sold under the brand name Pomalyst.

Other symbols: CI
18 days ago - Reuters

10 'Safer' Dividend Buys Of Barron's Better Bets Than T-Bills For June

Long-term bond yields continue to rise. But investors looking for income can still find plenty of attractive opportunities with dividend-paying stocks that have healthy yields. “23 stocks pay huge div...

Other symbols: BBYCAGEQRETRFRTKEYKIM
18 days ago - Seeking Alpha

I'm Buying Dividend Giants At Huge Discounts

Now is a great time to be an income and value investor, particularly in the energy and pharmaceutical spaces. I highlight 2 undervalued names that provide well-covered dividends with a strong growth o...

22 days ago - Seeking Alpha

Bristol Myers Squibb Announces Dividend

PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb Announces Dividend.

25 days ago - Business Wire

Bristol Myers Squibb Presents First Data from the Marginal Zone Lymphoma Cohort of the Transcend FL Trial Demonstrating Deep and Durable Responses with Breyanzi (lisocabtagene maraleucel)

PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #18ICML--BMS Presents First Data from the Marginal Zone Lymphoma Cohort of the Transcend FL Trial Demonstrating Deep and Durable Responses with Breyanzi.

26 days ago - Business Wire

Dividend Harvesting Portfolio Week 223: $22,300 Allocated, $2,310.77 In Projected Dividends

The Dividend Harvesting Portfolio hit a new all-time high, delivering a 26.95% return and $2,310.77 in forward annual dividend income. I continue to diversify across ETFs, REITs, CEFs, BDCs, and equit...

Other symbols: AREJEPIMOPDIQQQIVICI
4 weeks ago - Seeking Alpha

Bristol Myers Squibb Presents Data Across Targeted Protein Degradation Research Including CELMoD™ Agents and BCL6 Ligand-Directed Degrader at EHA 2025

PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #BMS--Bristol Myers Squibb Presents Data Across Targeted Protein Degradation Research Including CELMoD™ Agents and BCL6 Ligand-Directed Degrader at EHA 2025.

4 weeks ago - Business Wire

Bristol Myers Squibb to Report Results for Second Quarter 2025 on July 31, 2025

PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb to Report Results for Second Quarter 2025 on July 31, 2025.

4 weeks ago - Business Wire

Bristol-Myers Squibb Company (BMY) Presents at Goldman Sachs 46th Annual Global Healthcare Conference (Transcript)

Bristol-Myers Squibb Company (NYSE:BMY) Goldman Sachs 46th Annual Global Healthcare Conference June 11, 2025 10:00 AM ET Company Participants Adam Lenkowsky - Executive VP & Chief Commercialization O...

4 weeks ago - Seeking Alpha

Bristol Myers Squibb Presents Late-Breaking Data from Pivotal Phase 3 POETYK PsA-1 Trial Demonstrating Superiority of Sotyktu (deucravacitinib) Compared with Placebo in Adults with Psoriatic Arthritis

PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #EULAR--BMS Presents Late-Breaking Data from Pivotal Phase 3 POETYK PsA-1 Trial Demonstrating Superiority of Sotyktu.

4 weeks ago - Business Wire

Philochem AG Announces the Licensing of Worldwide Rights to OncoACP3, a novel Radiopharmaceutical Therapeutic and Diagnostic Agent targeting Prostate Cancer, to RayzeBio, a Bristol-Myers Squibb Company, for a potential value of up to $1.35bn plus royalties

Consideration composed of a $350m up-front payment and up to $1.0bn in development, regulatory and commercial milestones, along with mid-single to low double-digit royalties on Global Net Sales OTELFI...

4 weeks ago - GlobeNewsWire

5 Ideal 'Safe' Buys From June Fortune Return On Leadership Screen

Coincident to the June 5, 2025 annual launch of their Fortune 500, Fortune also partnered with Indiggo to measure Return On Leadership, called the ROL100. Arnold research focused on those 100 using YC...

Other symbols: ACICMCSACOPCVSCVXEPDET
4 weeks ago - Seeking Alpha

Bristol-Myers And BioNTech Deal: Good For Both Parties, But One Is The Better Investment

Bristol-Myers Squibb is attractively valued, offers a 5%+ dividend yield, and benefits from a strong oncology pipeline after its BioNTech deal. The $11B BioNTech partnership gives BMY access to BNT327...

Other symbols: BNTX
5 weeks ago - Seeking Alpha

Healthy Returns: AstraZeneca, Pfizer, Gilead and other drugmakers release promising cancer drug data at ASCO

Drugmakers unveil cancer drug data at the ASCO annual meeting, while Amazon Pharmacy announces new features for caregivers, Medicare patients.

Other symbols: AZNGILDPFEAMGNBNTXMRK
5 weeks ago - CNBC

Bristol Myers CEO explains why he's spending billions on BioNTech deal

Bristol-Myers Squibb Co (NYSE: BMY) is inching up on Monday after announcing an $11 billion deal with BioNTech SE (Nasdaq: BNTX) aimed at transforming cancer treatment. The pharmaceutical behemoth ann...

Other symbols: BNTX
5 weeks ago - Invezz